<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01074619</url>
  </required_header>
  <id_info>
    <org_study_id>04-087</org_study_id>
    <nct_id>NCT01074619</nct_id>
  </id_info>
  <brief_title>Study on Cognitive Disorders of Multiple Sclerosis</brief_title>
  <official_title>Effects of Memantine on Cognitive Disorders of Relapsing-remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if memantine is effective in the treatment on&#xD;
      cognitive disorders of Relapsing - Remitting multiple sclerosis. m&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pace Auditory Serial Addition Test(P.A.S.A.T)</measure>
    <time_frame>+1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Memantine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Remitting Multiple Sclerosis defined by Mc Donald et al., 2001&#xD;
&#xD;
          -  Patient with authorised immunomodulator treatment or oral immunosuppressive therapy&#xD;
             during more than three months: Bétâ Interferon, glatiramer acetate, azathioprine,&#xD;
             methotrexate, mycophenolate mofetil, treatment by monoclonal antibody I.V. or&#xD;
             anti-VLA4, natalizumab (Tysabri)&#xD;
&#xD;
          -  Patient having benefited, possibly, of following treatments : mitoxantrone,&#xD;
             cyclophosphamide, cyclosporine, general-purpose immunoglobulins, only if the treatment&#xD;
             is ended more of 6 months before the inclusion.&#xD;
&#xD;
          -  EDSS score ≤ 5.5&#xD;
&#xD;
          -  DRS score ≥ 130&#xD;
&#xD;
          -  PASAT 3s score &gt; 15 and &lt; median / control subjects according to 2 age brackets, sex,&#xD;
             school level.&#xD;
&#xD;
          -  Signed the informed consent form.&#xD;
&#xD;
          -  Effective contraception for women in age to procreate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Progressive form MS&#xD;
&#xD;
          -  MS relapse of less of 4 weeks.&#xD;
&#xD;
          -  IV or oral corticoid treatment in the month preceding the screening&#xD;
&#xD;
          -  Medicinal treatments or non medicinal in cognitive or psychology-stimulant aim in the&#xD;
             3 months before the screening&#xD;
&#xD;
          -  Tumoral form MS visible in the MRI.&#xD;
&#xD;
          -  Depressive syndrome (MADRS score &gt; 19).&#xD;
&#xD;
          -  Quite other diagnosed psychiatric pathology&#xD;
&#xD;
          -  Known allergy or quite contraindication in memantin : renal or hepatic insufficiency,&#xD;
             turned out epileptic disease, treatment by ketamine, amantadin, dextromethorphan,&#xD;
             L-Dopa, dopaminergic agonist, barbituric, neuroleptic, 3,4-diaminopyridine, lithium,&#xD;
             cimetidine, ranitidine, procainamide, quinine, nicotine, hydrochlorthiazide and ally,&#xD;
             phenytoin, modafinil.&#xD;
&#xD;
          -  Recent treatment (less of 4 weeks) by antidepressants and/or anxiolytics.&#xD;
&#xD;
          -  Pregnancy or feeding.&#xD;
&#xD;
          -  Minor or Major &quot;protected by the law&quot; patient&#xD;
&#xD;
          -  Uncontrolled diet.&#xD;
&#xD;
          -  Patient having benefited of one psychometric assessment(including in particular tests&#xD;
             planned in the protocol) since less of one year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Defer Gilles, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Caen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>February 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2010</study_first_posted>
  <last_update_submitted>August 31, 2012</last_update_submitted>
  <last_update_submitted_qc>August 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

